SAN ANTONIO– bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales. Mr. Coleman has more than 15 years of experience in medical sales and marketing, most recently as Executive Account Manager for the respiratory portfolio of Olympus America’s therapeutic solutions division.
Reporting to bioAffinity Technologies President and Chief Executive Officer Maria Zannes, Mr. Coleman is responsible for leading the CyPath® Lung sales team and sourcing new business opportunities.
“We are delighted to welcome Dallas to our management team in this newly created position. His experience and demonstrated track record in building strong relationships with our target customers and creating effective sales organizations is a timely and strategic fit as we ramp up the commercialization of CyPath® Lung, our noninvasive test for the detection of early-stage lung cancer,” Ms. Zannes said. “As a near-term priority, his expertise in developing commercial initiatives is expected to help drive the expansion of our pilot market launch across Texas and pave the way for the national rollout of CyPath® Lung.”
At Olympus America, Mr. Coleman was part of a team that launched new products, including spiration valves for COPD and emphysema patients, navigational bronchoscopy to access peripheral nodules, and ultrasound bronchoscopes used to sample lymph nodes for cancer staging, primarily marketing to pulmonologists, interventional pulmonologists, thoracic surgeons and physicians treating patients with lung disease. Prior to that, he held sales management positions at Caldera Medical, a medical device company focused on women’s health, and Ecolab, a global sustainability leader providing water, hygiene and hospital infection prevention solutions and services.
“My career has consistently revolved around extending the lives of patients and improving their quality of life. For the past five years, I have provided physicians and hospitals with innovative devices for the diagnosis and treatment of pulmonary diseases, including lung cancer,” Mr. Coleman said. “More than 14 million Americans are at high risk for lung cancer, and the opportunity to share CyPath® Lung with their care teams is highly motivating. I look forward to working with my new colleagues at bioAffinity to accelerate the rollout of this innovative product and help physicians treat lung cancer in its early stages, with better outcomes for patients.”
